Table 5.

Number (%) of patients reporting common adverse events (≥2% in any group) by preferred term (safety set)

Preferred term, n (%)	Vildagliptin + metformin n = 68	Placebo + metformin n = 70
Any preferred term	30 (44.1)	29 (41.4)
Nasopharyngitis	5 (7.4)	4 (5.7)
Amylase increased	4 (5.9)	1 (1.4)
Dental caries	2 (2.9)	0 (0.0)
Gastritis erosive	2 (2.9)	0 (0.0)
Tinea infection	2 (2.9)	0 (0.0)
Lipase increased	2 (2.9)	1 (1.4)
Hypoesthesia	2 (2.9)	0 (0.0)
Anemia	0 (0.0)	3 (4.3)
Diarrhea	0 (0.0)	2 (2.9)
Gastroenteritis	0 (0.0)	2 (2.9)
Alanine aminotransferase increased	0 (0.0)	2 (2.9)
Aspartate aminotransferase increased	0 (0.0)	2 (2.9)
Back pain	0 (0.0)	2 (2.9)
Headache	0 (0.0)	2 (2.9)
Tension headache	0 (0.0)	2 (2.9)